Panacea Biotec Peer Comparison

NSE: PANACEABIO | BSE: 531349

₹372.60

₹-2.15 (-0.57%)

As on 25-Sep-2026IST

Market cap

₹2,281 Cr

Revenue (TTM)

₹673 Cr

P/E Ratio

P/B Ratio

2.7

Div. Yield

0 %

Edit

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Market cap (₹ Cr)	2,281	21,555	19,802	18,323	17,490
Revenue (₹ Cr)	673	2,287	1,682	2,570	3,230
Net Profit (₹ Cr)	-8.92	678.07	273.51	735.15	666.92
Net Margin (%)	-1.30	28.10	16.19	26.88	20.60
RoE (%)	-1.37	19.73	11.15	19.16	18.75
Price to Earnings	--	32.40	66.60	24.92	27.16
Price-To-Book	2.73	5.87	7.37	4.16	4.34

Income Statement (₹ Cr)

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Operating Revenue	672.64	2,287.33	1,682.47	2,569.77	3,229.67
Total Income	688.11	2,413.29	1,689.83	2,735.39	3,237.12
Total Expenditure	670.45	1,490.75	1,203.91	1,628.14	2,090.06
EBITDA	2.19	796.58	478.55	941.63	1,139.61
Depreciation	32.57	78.10	126.01	57.58	281.06
EBIT	-30.38	718.48	352.55	884.05	858.55
Interest	6.37	0.88	52.11	7.69	190.64
Other Income	15.47	125.96	7.37	165.62	7.45
Exceptional Items	10.92	0.00	12.16	-49.16	-17.24
Profit before Tax	-10.36	843.56	319.96	992.82	658.12
Provision for Tax	-1.44	165.49	46.45	257.67	-8.80
Profit after Tax	-8.92	678.07	273.51	735.15	666.92

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Shareholder's Funds	834.84	3,586.42	2,591.20	4,202.90	3,902.67
Minority Interest	1.80	-12.71	0.00	0.00	-21.81
Non-Current Liabilities	84.61	28.74	266.35	91.50	1,392.75
Current Liabilities	348.68	385.94	848.06	627.48	2,077.10
Total Liabilities	1,262.18	4,037.51	3,705.61	4,921.88	7,246.72

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Non-Current Assets	719.70	1,291.22	2,525.44	770.28	5,617.77
Current Assets	513.04	2,585.66	1,109.77	3,803.22	1,539.85
Total Assets	1,262.18	4,037.51	3,705.61	4,921.88	7,246.72
Total Debt*	23.66	0.57	657.97	2.50	2,309.68
Net Current Assets	164.36	2,199.72	261.71	3,175.74	-537.25
Contingent Liabilities	416.47	17.53	160.01	370.49	51.57

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Cash From Operating Activities	16.69	523.24	342.18	967.57	537.99
Cash Flow from Investing Activities	-40.50	-582.30	-325.92	-561.67	-369.46
Cash from Financing Activities	-1.06	-46.46	13.62	-798.31	-313.53
Net Cash Inflow / Outflow	-24.86	-105.52	29.88	-392.41	-145.00

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
ROCE (%)	-0.15	24.97	11.43	23.39	14.47
ROE (%)	-1.37	19.73	11.15	19.16	18.75
ROA (%)	-0.70	18.69	7.80	14.95	9.26
EBIT Margin (%)	-4.52	31.41	20.95	34.40	26.58
Net Margin (%)	-1.30	28.10	16.19	26.88	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Revenue Growth (%)	10.26	15.01	27.91	10.69	9.59
EBIT Growth (%)	36.14	18.45	58.32	24.14	16.84
Net Profit Growth (%)	-180.22	19.61	149.56	-9.09	62.68
EPS Growth (%)	99.13	17.73	-3.57	14.40	67.41
Book Value Growth (%)	0.01	26.75	9.67	-0.34	36.71

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Price / Earnings	-199.78	32.40	70.65	23.75	26.48
Price / Book Value	2.73	5.87	7.37	4.16	4.34
Dividend Yield (%)	0.00	0.28	0.06	1.87	0.00
EV/EBITDA	1,018.37	25.80	42.66	16.16	17.32
Market Cap (₹ Cr)	1,813.89	11,439.22	6,819.66	21,592.90	17,980.08

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debt to Equity	0.03	0.00	0.07	0.00	0.24
Short term debt to equity ratio	--	0.00	0.16	0.00	0.12
Current Ratio	1.47	6.70	1.31	6.06	0.74
Quick Ratio	0.92	5.59	0.88	5.31	0.53
Interest Coverage	-0.63	959.59	7.14	130.11	4.45

	Panacea Biotec	Caplin Point Lab	Shilpa Medicare	Pfizer	Eris Lifesciences
Debtors to sales (%)	10.93	36.10	30.84	7.07	21.07
Asset Turnover	0.53	0.63	0.48	0.52	0.45
Receivable days	40.93	121.68	113.81	26.06	63.88
Inventory Days	113.89	63.83	84.76	65.95	43.27
Payable days	270.26	108.28	101.94	81.01	151.85
Cash Conversion Cycle	-115.43	77.23	96.62	11.00	-44.70

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.